Press Releases


New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent

January 26, 2021

Tags |  Product

- BLAZE-1 trial met primary endpoint and key secondary endpoints with high statistical significance - Results from more than 1,000 high-risk patients were consistent with previous data - Findings from BLAZE-4 trial provide data on lower doses of bamlanivimab and etesevimab together - Media and




Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents

January 21, 2021

Tags |  Product

INDIANAPOLIS , Jan. 21, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The Phase 3 BLAZE-2 COVID-19 prevention trial – conducted in




US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

January 11, 2021

Tags |  Product

RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 11, 2021 /PRNewswire/ -- The U.S.   Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance ® (empagliflozin) which is being investigated as a potential new treatment to reduce the risk of cardiovascular death




Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial

January 11, 2021

Tags |  Product

INDIANAPOLIS , Jan. 11, 2021 /PRNewswire/ -- Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer's disease compared




Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico

December 18, 2020

Tags |  Product

Study will provide real-world data and insight on various infusion setting experiences Plan to study bamlanivimab in a diverse group of participants, including Native American communities INDIANAPOLIS , Dec. 18, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced plans to begin




Lilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study

December 14, 2020

Tags |  Product

- New IDEAS study will focus on African American and Latino participants - Study to further assess the utility of amyloid brain PET scans for Alzheimer's Disease and other causes of cognitive decline INDIANAPOLIS , Dec. 14, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced




Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine

December 11, 2020

Tags |  Product

INDIANAPOLIS , Dec. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine   has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy




Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio®

December 9, 2020

Tags |  Product

Pre-planned primary outcome analysis continues to show clinically significant improvement in invasive disease-free survival as data mature for people with HR+, HER2- high risk early breast cancer New data presented includes an additional 3.6 months of follow-up and more than 1400 patients




Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes

December 9, 2020

Tags |  Product

More than half of participants taking the highest dose achieved normal A1C levels, a key secondary endpoint in first phase 3 trial of SURPASS program Participants in this monotherapy study had relatively recently diagnosed diabetes, with a mean duration of 4.7 years INDIANAPOLIS , Dec.




Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting

December 7, 2020

Tags |  Product

62% overall response rate in BTK pre-treated CLL/SLL patients, rising to 84% in patients followed for 10 or more months; consistent response rates regardless of reason for prior BTK discontinuation or BTK mutation status Similar overall response rates observed in patients previously treated with